ArticleThe international journal of biostatistics2011
Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.
Article in The international journal of biostatistics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.The Journal of infectious diseases · 2014Trial
- Computational tools and data integration to accelerate vaccine development: challenges, opportunities, and future directions.Frontiers in immunology · 2025Review
- A controlled effects approach to assessing immune correlates of protection.Biostatistics (Oxford, England) · 2023Article
- Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials.Biometrics · 2021Article
- Dealing with death when studying disease or physiological marker: the stochastic system approach to causality.Lifetime data analysis · 2019Article
- Evaluation and comparison of predictive individual-level general surrogates.Biostatistics (Oxford, England) · 2018Article
- A method to address between-subject heterogeneity for identification of principal surrogate markers in repeated low-dose challenge HIV vaccine studies.Statistics in medicine · 2017Article
- Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition.Journal of causal inference · 2015Article
- Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.Clinical trials (London, England) · 2015Article
- Design and estimation for evaluating principal surrogate markers in vaccine trials.Biometrics · 2013Article
- The causal mediation formula--a guide to the assessment of pathways and mechanisms.Prevention science : the official journal of the Society for Prevention Research · 2012Article
- Nomenclature for immune correlates of protection after vaccination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Article
- Immune-correlates analysis of an HIV-1 vaccine efficacy trial.The New England journal of medicine · 2012Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
This commentary takes up Pearl's welcome challenge to clearly articulate the scientific value of principal stratification estimands that we and colleagues have investigated, in the area of randomized placebo-controlled preventive vaccine efficacy trials, especially trials of HIV vaccines. After briefly arguing that certain principal stratification estimands for studying vaccine effects on post-infection outcomes are of genuine scientific interest, the bulk of our commentary argues that the "causal effect predictiveness" (CEP) principal stratification estimand for evaluating immune biomarkers as surrogate endpoints is not of ultimate scientific interest, because it evaluates surrogacy restricted to the setting of a particular vaccine efficacy trial, but is nevertheless useful for guiding the selection of primary immune biomarker endpoints in Phase I/II vaccine trials and for facilitating assessment of transportability/bridging surrogacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.